학술논문
1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC
Document Type
Abstract
Author
Source
In Annals of Oncology September 2020 31 Supplement 4:S891-S892
Subject
Language
ISSN
0923-7534